ReviewDevelopmental period medicine2019
Pneumocystis pneumonia: still a serious disease in children.
Review in Developmental period medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global prevalence, mortality, and main characteristics of HIV-associated pneumocystosis: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Pooled it
- Clinical Features, Laboratory and Radiological Findings, and Outcomes ofBalkan medical journal · 2026Article
- Metagenomic next-generation sequencing to detect Pneumocystis jirovecii pneumonia in critically ill, HIV-negative children: a retrospective multicenter study.BMC pulmonary medicine · 2026Observational
- Development of a vaccine construct againstNAR genomics and bioinformatics · 2025Article
- Respiratory infection induced episode of alveolar hemorrhage (RIIEAH) in the pediatric diffuse alveolar hemorrhage: a retrospective single-center study.BMC pediatrics · 2025Article
- CRISPR-mediated detection of Pneumocystis transcripts in bronchoalveolar, oropharyngeal, and serum specimens for Pneumocystis pneumonia diagnosis.The Journal of clinical investigation · 2025Article
- The efficacy of nebulized budesonide and ambroxol hydrochloride in treating pediatric community-acquired pneumonia and their impact on clinical characteristics and inflammatory markers.Journal of health, population, and nutrition · 2024Article
- Metagenomic next-generation sequencing promotes diagnosis and treatment of Pneumocystis jirovecii pneumonia in non-HIV infected children: a retrospective study.BMC pulmonary medicine · 2024Article
- Study on mNGS Technique in DiagnosingInfection and drug resistance · 2024Article
- Clinical Pharmacist Involved in the Treatment ofInfection and drug resistance · 2024Article
- NovelJournal of fungi (Basel, Switzerland) · 2023Article
- Metagenomic next-generation sequencing for the diagnosis of Pneumocystis jirovecii Pneumonia in critically pediatric patients.Annals of clinical microbiology and antimicrobials · 2023Article
- Article
- Microbial lectome versus host glycolipidome: How pathogens exploit glycosphingolipids to invade, dupe or kill.Frontiers in microbiology · 2022Review
- Immunization with Pneumocystis carinii A12BMC immunology · 2021Article
- Toward a humanized mouse model of Pneumocystis pneumonia.JCI insight · 2021Article
- Diagnosis ofJournal of fungi (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumocystis carinii pneumonia is a common opportunistic respiratory infection among children with human immunodeficiency virus and a weakened immune system. The primary infection in immunocompetent patients may be asymptomatic, whereas fever, shortness of breath, night sweats, nonproductive (dry) cough, pneumonia, progressive respiratory distress and apnea are cardinal symptoms of full-blown pneumocystis pneumonia. The diagnosis can be confirmed by histochemical staining of biological specimens or, recently, by polymerase chain reaction. International recommendations indicate that the drug of choice is the intravenously administered trimethoprim-sulfamethoxazole combination. Early diagnosis and appropriate treatment reduce the mortality of the disease. This article briefly highlights the epidemiology of Pneumocystis pneumonia, its diagnosis and therapeutic options in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.